HLB Life Science Co - Stock

HLB Life Science Co Stocks 2024

HLB Life Science Co Stocks

104.45 M

Ticker

067630.KQ

ISIN

KR7067630004

In 2024, HLB Life Science Co had 104.45 M outstanding stocks, a 0.8% change from the 103.62 M stocks in the previous year.

The HLB Life Science Co Stocks history

YEARNUMBER OF STOCKS (undefined KRW)
2023104.45
2022103.62
2021101.95
202094
201988
201857
201751
201651
201534
201428
201317
201216
201116

HLB Life Science Co shares outstanding

The number of shares was HLB Life Science Co in 2023 — This indicates how many shares 104.447 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue HLB Life Science Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates HLB Life Science Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of HLB Life Science Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating HLB Life Science Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

HLB Life Science Co Aktienanalyse

What does HLB Life Science Co do?

HLB Life Science Co., Ltd. is a leading company in the research, development, and production of biotechnological and pharmaceutical products. The company was founded in 2015 in Seoul, South Korea. Due to the founders' extensive experience in the field of life science and biotechnology, HLB Life Science has quickly established itself as a key player in the industry. HLB Life Science's business model is based on the development and production of innovative biotechnological and pharmaceutical products, as well as collaboration with other companies and research institutions. The aim is to improve people's quality of life by providing effective and safe medications and therapies. The company is divided into various divisions. The Biopharmaceuticals division includes the development and production of biotechnological products such as antibodies, proteins, vaccines, and diagnostics. The Pharmaceuticals division develops and produces advanced drugs in the field of oncology, immunology, and neurology. The Clinical Research Services division offers contract research services in the field of clinical studies to test the effectiveness and safety of drugs. In addition, HLB Life Science Co., Ltd. is also active in the Nutra-Pharmaceuticals division, specializing in the development and production of dietary supplements. HLB Life Science offers various products tailored to the needs of patients. In the field of Biopharmaceuticals, for example, the company produces antibodies and proteins for the treatment of cancer, inflammatory diseases, and infections. Another innovative product is a fully humanized antibody against the hepatitis B virus, which is one of the most common liver diseases. In the Pharmaceuticals field, HLB Life Science offers innovative drugs for the treatment of cancer, autoimmune diseases, and neurological disorders. In the Nutra-Pharmaceuticals field, the company offers dietary supplements based on natural ingredients that can strengthen the immune system. HLB Life Science Co., Ltd. is known in the industry for its innovative strength and excellent research results. The company places great emphasis on continuous research and development to develop innovative products and continuously improve existing products. Due to their outstanding products and services, HLB Life Science has already exported to various countries worldwide and has thus played a significant role in the global market. Looking to the future, HLB Life Science Co., Ltd. continues to focus on innovative research and development, as well as close collaboration with universities and research institutions. The company aims to improve people's health and well-being through effective and safe medications and therapies. HLB Life Science Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating HLB Life Science Co's Shares Outstanding

HLB Life Science Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in HLB Life Science Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding HLB Life Science Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in HLB Life Science Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about HLB Life Science Co stock

How many stocks are there of HLB Life Science Co?

The current number of stocks of HLB Life Science Co is 104.45 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of HLB Life Science Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of HLB Life Science Co evolved in recent years?

The number of shares of HLB Life Science Co has increased by 0.8% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. HLB Life Science Co as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of HLB Life Science Co?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does HLB Life Science Co pay?

Over the past 12 months, HLB Life Science Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HLB Life Science Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of HLB Life Science Co?

The current dividend yield of HLB Life Science Co is .

When does HLB Life Science Co pay dividends?

HLB Life Science Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of HLB Life Science Co?

HLB Life Science Co paid dividends every year for the past 0 years.

What is the dividend of HLB Life Science Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is HLB Life Science Co located?

HLB Life Science Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von HLB Life Science Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of HLB Life Science Co from 7/7/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 7/7/2024.

When did HLB Life Science Co pay the last dividend?

The last dividend was paid out on 7/7/2024.

What was the dividend of HLB Life Science Co in the year 2023?

In the year 2023, HLB Life Science Co distributed 0 KRW as dividends.

In which currency does HLB Life Science Co pay out the dividend?

The dividends of HLB Life Science Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von HLB Life Science Co

Our stock analysis for HLB Life Science Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLB Life Science Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.